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Background/introduction: Early reports of stereotactic body radiation therapy (SBRT)
for pancreatic ductal adenocarcinoma (PDAC) used single fraction, but eventually shifted
to multifraction regimens. We conducted a single institution review of our patients treated
with single- or multifraction SBRT to determine whether any outcome differences existed.
Methods and materials: Patients treated with SBRT in any setting for PDAC at our
facility were included, from 2004 to 2014. Overall survival (OS), local control (LC), regional
control (RC), distant metastasis (DM), and late grade 3 or greater radiation toxicities from
the time of SBRT were calculated using Kaplan–Meier estimation to either the date of
last follow-up/death or local/regional/distant failure.
Results: We identified 289 patients (291 lesions) with pathologically confirmed PDAC.
Median age was 69 (range, 33–90) years. Median gross tumor volume was 12.3 (8.6–
21.3) cm3 and planning target volume 17.9 (12–27) cm3. Single fraction was used in 90
(30.9%) and multifraction in 201 (69.1%) lesions. At a median follow-up of 17.3 months
(IQR 10.1–29.3 months), the median survival for the entire cohort 17.8 months with
a 2-year OS of 35.3%. Univariate analysis showed multifraction schemes to have a
higher 2-year OS 30.5% vs. 37.5% (p = 0.019), it did not hold significance on MVA.
Multifractionation schemes were found to have a higher LC on MVA (HR = 0.53, 95% CI,
0.33–0.85, p = 0.009). At 2 years, late grade 3+ toxicity was 2.5%. Post-SBRT CA19-9
was found on MVA to be a prognostic factor for OS (HR = 1.01, 95% CI, 1.01–1.01,
p = 0.009), RC (HR = 1.01, 95% CI 1.01–1.01, p = 0.02), and DM (HR = 1.01, 95% CI,
1.01–1.01, p = 0.001).
Conclusion: Our single institution retrospective review is the largest to date comparing
single and multifraction SBRT and the first to show multifraction regimen SBRT to have a
higher LC than single fractionation. Additionally, we show low rates of severe late toxicity
with SBRT.
Keywords: pancreatic adenocarcinoma, stereotactic body radiation therapy, overall survival, local control,
fractionation, toxicity
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INTRODUCTION

Inc., Sunnyvale, CA, USA) or non-robotic linear accelerator
based platforms (Trilogy, TrueBeam) (Varian Medical Systems,
Palo Alto, CA, USA). Patient variables including age, race, gender,
SMAD4 mutation, surgical status, chemotherapy treatment, prior
EBRT, and SBRT dose, dosimetry, and advanced toxicities were
collected.

Pancreatic carcinoma is an aggressive malignancy with a predicted 53,070 new cases and 41,780 deaths in the US in 2016 with
a 5-year survival of only 7% (1). Currently, tumor resectability is
the single most powerful prognostic factor with surgery allowing
the only practical chance for cure (2). Systemic chemotherapy
and radiation, however, have been shown to play an important
role as adjuvant therapy. Unfortunately, less than 20% of patients
are deemed surgical candidates at time of presentation due to the
commonly advanced presentation of disease (3, 4).
Historically, radiation therapy for pancreatic adenocarcinoma
consisted of 6 weeks of external beam radiation therapy (EBRT)
which was associated with significant toxicity and delayed time
to systemically dosed chemotherapy (5). Drawing upon the
success of stereotactic radiosurgery in the treatment of intracranial tumors, stereotactic body radiation therapy (SBRT) was
developed in order to deliver a hypofractioned treatment to
extracranial tumors (6, 7). Using high precision, this can deliver
a high biological effective dose to the tumor while minimizing
dose to surrounding tissue (8).
Recently, SBRT has demonstrated utility as primary treatment in unresectable disease, neoadjuvant treatment in locally
advanced disease, and adjuvant therapy for resected and recurrent pancreatic tumors (9–14). Due to the shorter duration of
treatment in SBRT over standard EBRT, patients receive full dose
systemic chemotherapy with less delay. Importantly, studies show
SBRT to have excellent local control (LC) and minimal toxicity
rates while remaining a cost-effective treatment option (15–17).
Initial experience with SBRT for pancreatic adenocarcinoma
primarily used single fraction regimens however were complicated by relatively high rates of late GI toxicity (11, 18, 19). Later
experiences used multifraction regimens were implemented and
have since been shown to limit late GI toxicity (20). Data comparing single- to multifraction regimens, however remain limited
and are unclear whether there are any other differences in these
treatments besides toxicity rates. We therefore aim to compare
single to multifraction SBRT for pancreatic cancer to distinguish
possible differences in control rates, overall survival (OS), and
toxicity.

Definition of Parameters

Resectable status was determined by a multidisciplinary case
review using NCCN guidelines for resectable, borderline resectable, and unresectable disease. Local, regional, and distant
progression were determined based on radiographic findings on
follow up and/or confirmatory biopsy if done. Local progression
was identified as progressive disease using RECIST 1.1 criteria.
This is characterized by at least a 20% increase in the sum of
diameters of the tumor with minimum of a 5 mm increase (21).
Regional failure was defined as disease progression to the regional
nodes defined as n1, n2, or n3 by the JPS classification (22, 23)
(or new tumor growth within the pancreas outside of the radiation field). Toxicity was graded retroactively with the Common
Terminology Criteria for Adverse Events Version 4.0 (CTCAE
4.0). Patients included in this review were simulated in the supine
position using four-dimensional CT scan with IV contrast in a
vacuum lock bag and wingboard. The 4D-CT scan was obtained
utilizing 1.25 mm slices simulated in a vacuum lock bag. During
the time of simulation, a motion study was performed during
which we obtained multiple images during the respiratory cycle
using the abdominal marker as a surrogate for the respiratory
cycle. The signal detected from the abdominal surrogate was used
to bin the CT images, creating a series of separate CT scans for
each phase in the breathing cycle. We then contoured the gross
tumor volume (GTV) to see whether any motion was detected
during the breathing cycles. If the motion was found to be
more than 5 mm, we decided to use respiratory gating. In this
technique, we determined which phases of the breathing cycle
limit the tumor motion to 5 mm and treat during those specific
phases. During the patient’s treatment, an equivalent abdominal
surrogate signal is used to control the beam on time of the linear
accelerator. The GTV was determined based on the simulation
CT scan and diagnostic CT scans. The planning target volume
(PTV) margin was added to be approximately 3 mm from GTV
with editing off of the bowel (Figure 1). Patients included in the
study had fiducials placed before CT-simulation to assist with
target delineation during treatment. The bowel was our major
dose limiting structured and was limited to no more than 30 Gy
maximum. The max dose for the kidneys, liver, and cord were
limited to 15, 50, and 15 Gy, respectively. Notably two patients
exceeded the max dose for the right kidney (29.0 and 18.3 Gy),
and one patient exceeded the max dose for the cord (27.6 Gy).

MATERIALS AND METHODS
Patient Population

Following approval from our institutional review board, we
reviewed patients with histologically proven pancreatic adenocarcinoma treated with SBRT in either one or three fractions
between 2004 and 2014. Patients received SBRT as neoadjuvant,
adjuvant, or definitive treatment. Patients with resectable,
borderline resectable, unresectable, medically inoperable, and
recurrent tumors were included in this study. Patients with distant metastasis (DM) at diagnosis (who were provided SBRT for
symptom control) were excluded as well as one additional patient
excluded for having no records other than SBRT date and dose.
Patients included in the study were staged clinically, with the use
of CT scans and endoscopic ultrasound techniques. SBRT was
performed on either a CyberKnife robotic radiosurgery (Accuray
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Statistical Analysis

Overall survival, LC, regional control (RC), DM, and advanced
grade 3 or greater radiation toxicities from the time of SBRT were
calculated using Kaplan–Meier estimation to either the date of
last follow-up/death or local/regional/distant failure. Predictive
factors for OS, LC, RC, DM, and advanced toxicities were determined through use of univariate log-rank test or Cox regression
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Figure 1 | Example stereotactic body radiation therapy plan for pancreatic adenocarcinoma with gross tumor volume highlighted in red, planning target volume
highlighted in orange and 85% isodose highlighted in dose heatmap.

SBRT Treatment Characteristics

analysis. Those variables deemed significant (p < 0.05) were
incorporated into multivariable survival analyses using forward
stepwise selection in a Cox proportional hazards regression
model. Statistical significance was set with a two-sided p-value
of <0.05. Statistical analysis was performed using IBM SPSS
Statistics version 23.

Stereotactic body radiation therapy was delivered by Trilogy
(41.2%), Truebeam (34.1%), or CyberKnife (24.7%) in either one
fraction (30.9%) or multiple fractions (69.1%). Median dose was
24 Gy (range 18–25) for single fraction and 36 Gy (range 24–36) for
three fractions. One patient received 24 Gy in two fractions with
all others receiving three-fraction regimens if treated in multiple
fractions. For the entire cohort, GTV was 12.3 cm3 (IQR 8.6–21.3)
and PTV was 17.9 cm3 (IQR 12–17). For patients who received
neoadjuvant SBRT, the median time to surgery was 1.8 months
(IQR 1.44–3.84). For those who received adjuvant SBRT, the
median time from surgery was 3.77 months (IQR 2.17–12.15).

RESULTS
Patient Characteristics

A detailed list of patient characteristics can be found in Table 1.
We identified 289 patients with 291 lesions treated with SBRT
of pancreatic adenocarcinoma with a median age at diagnosis of
69 (range 33–90) with 49.8% female and 50.2% male. Tumors
were located in the head (62.9%), body (11%), uncinate process
(7.6%), neck (4.8%), tail (2.7%), and genu (0.3%) of the pancreas.
Multifocal disease as defined by two or more lesions within the
pancreas was seen in 10.7%. SMAD4 mutation status was collected and positive in 10% and unknown in 78.7% of lesions.
Recurrent lesions represented 13.4% of the total and 13.1% of the
total lesions received prior EBRT with a median dose of 50.4 Gy
in 2–8 fractions (IQR, 30–50.4). Chemotherapy was given to
82.1% of patients and 55.0% received neoadjuvant chemotherapy.
Surgical status at diagnosis, deemed in a multidisciplinary case
review, included resectable (entire cohort: 39.2%, single fraction: 41.3%, multifraction: 37.7%), borderline resectable (entire
cohort: 14.0%, single fraction: 2.2%, multifraction: 19.1%),
locally advanced/unresectable (entire cohort: 42.3%, single
fraction: 55.4%, multifraction:37.2%), and medically inoperable
(entire cohort:4.5%, single fraction: 1.1%, multifraction: 6.0).
Surgical resection was performed on 46.7, 44.6, and 47.7% of the
entire cohort, single fraction patients, and multifraction patients,
respectively.

Frontiers in Oncology | www.frontiersin.org

Overall Survival

At a median follow-up of 17.3 months (IQR 10.1–29.3 months),
the median survival for the entire cohort was 17.8 months with a
2-year OS of 35.3% (Table 2). Univariate analysis demonstrated
superior 2-year survival was significantly associated with age
(p < 0.001), pre-SBRT CA19-9 (p < 0.001), post-SBRT CA19-9
(p = 0.011), non-robotic treatment platform (p = 0.013), PTV
volume (p < 0.001), recurrent lesions (p = 0.001), surgery
(p < 0.001), and multifraction SBRT (p = 0.019). While univariate
analysis showed multifraction schemes to have a higher 2-year
OS 30.5% vs. 37.5%, it did not hold significance on multivariate
analysis. Only surgery [p = < 0.001, HR 0.31 (95% CI, 0.19–0.51)]
and post-SBRT CA19-9 [p = 0.009, HR 1.01 (95% CI, 1.01–1.01)]
maintained significance on multivariate analysis (Table 3). For
patients receiving resection, 2-year OS was 59.8% compared to
14.3% for those not receiving surgical resection.

Local Control

Two-year LC was 66.1% for the entire cohort, 56.8% for single
fraction, and 69.7% for multifraction SBRT (Figure 2). Univariate
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TABLE 1 | Continued

Table 1 | Patient characteristics.
Characteristics
Age (years, range)

Value (n = 291 lesions)
69 (33–90)

Gender
Female
Male

145 (49.8%)
146 (50.2%)

CA19-9 value (median value, IQR)
At diagnosis
Pre-SBRT
Post-SBRT

221(80–733)
81 (21–378)
73 (23–342)

SMAD4 mutated
No
Yes
Unknown

33 (11.3%)
29 (10%)
229 (78.7%)

Surgical status
Resectable entire cohort
Resectable single fraction
Resectable multifraction
Borderline resectable
Borderline resectable single fraction
Borderline resectable multifraction
Unresectable
Unresectable single fraction
Unresectable multifraction
Medically inoperable
Medically inoperable single fraction
Medically inoperable multifraction

112 (39.2%)
38 (41.3%)a
75 (37.6%)b
40 (14.0%)
2 (2.2%)a
38 (19.1%)b
121 (41.5%)
51 (55.4%)a
74 (37.2%)b
13 (4.5%)
1 (1.1%)a
12 (6.0%)b

Surgery
Yes entire cohort
Yes single fraction
Yes multifraction
No entire cohort
No single fraction
No multifraction

136 (46.7%)
41 (44.6%)a
95 (47.7%)b
155 (53.3%)
51 (55.4%)a
105 (52.3%)b

Any chemotherapy
Yes
No
Unknown

239 (82.1%)
42 (14.4%)
10 (3.4%)

Neoadjuvant chemotherapy
Yes
No
Unknown

160 (55%)
115 (39.5%)
16 (5.5%)

Location
Body
Heal
Tail
Uncinate
Neck
Genu
Multiple

32 (11%)
183 (62.9%)
8 (2.7%)
22 (7.6%)
14 (4.8%)
1 (0.3%)
31 (10.7%)

Prior EBRT
Yes
No
Previous EBRT dose (median, IQR)

38 (13.1%)
253 (86.9%)
50.4 (30–50.4)

Treatment platform
Trilogy
CyberKnife
Truebeam

120 (41.2%)
72 (24.7%)
99 (34%)

252 (86.6%)

GTV (cm3) (median, IQR)

12.3 (8.6–21.3)

PTV (cm3) (median, IQR)

17.9 (12–27)

Fractionation
Single
Multifraction

90 (30.9%)
201 (69.1%)

Dose
18 Gy in 1 fraction
20 Gy in 1 fraction
20 Gy in 2 fractions
22 Gy in 1 fraction
24 Gy in 1 fraction
24 Gy in 2 fraction
24 Gy in 3 fraction
25 Gy in 1 fraction
27 Gy in 3 fractions
30 Gy in 3 fractions
36 Gy in 3 fractions

2 (0.7%)
4 (1.4%)
1 (0.3%)
17 (5.8%)
62 (21.3%)
1 (0.3%)
2 (0.7%)
5 (1.7%)
7 (2.4%)
28 (9.6%)
162 (55.7%)
180 Gy10 (180–183.3)

Percentages out of the 92 patients who received single-fraction SBRT.
Percentages out of the 199 patients who received multifraction SBRT.
SBRT, stereotactic body radiation therapy.
a

b

analysis demonstrated superior 2-year LC significantly associated with treatment platform (p = 0.002), non-recurrent
lesions (p < 0.001), surgery (p = 0.01), and multifraction SBRT
(p = 0.004). Two-year LC for patients who received surgical
resection was 74.1 vs. 53.9% for those who did not. On multivariate analysis, multifractionation [p = 0.009, HR 0.53 (95% CI,
0.33–0.85)] was associated with higher LC, whereas recurrent
lesions led to lower LC [p = 0.003, HR 2.31 (95% CI, 1.32–4.05)]
(Table 4). Two-year LC for recurrent lesions was 35.4% compared
to 70.4% for non-recurrent lesions.

RC and Distant Metastases

One- and two-year RC rates were 89.2 and 86.3%, respectively.
A higher post-SBRT CA19-9 was the only variable found to
be significantly associated with inferior RC on univariate and
multivariate analysis [p = 0.02, HR 1.01 (95% CI, 1.01–1.01)]
(Table 5). At one and two years, the Kaplan–Meier estimated
rate of DM was 39.5 and 56.4%, respectively. Univariate analysis
identified CA19-9 at diagnosis (p = 0.041), pre-SBRT CA 19-9
(p = 0.001), and post-SBRT CA 19-9 (p = 0.006) associated
with increased distant metastases. Post-SBRT CA19-9 was the
only variable to maintain significance on multivariate analysis
[p = 0.001, HR 1.01 (95% CI, 1.01–1.01)] (Table 5). Treatment
fractionation was not found to be associated with either RC or
distant metastases.

Late Radiation Toxicity

For the entire cohort, the Kaplan–Meier estimated advanced
grade 3+ toxicity rate at 1- and 2-years was 2.5% (95% CI,
2.3–2.7%) advanced grade. No significant difference was noted
based on single- or multifraction use (2-year advanced grade 3+

39 (13.4%)
(Continued)
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No

BED10 Gy
Median (IQ range)

Recurrent lesion
Yes

Value (n = 291 lesions)

Characteristics
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toxicity estimate 2.3 vs. 2.8%, p = 0.747). Prior radiation therapy
was the only factor predictive of advanced grade 3+ toxicity
[p = 0.019, HR 4.58 (95% CI, 1.29–16.21)] (Table 6). For patients
who received surgery, advanced grade 3+ toxicity rate at 2-years
was 1.8% compared to 3.2% for non-surgical patients (p = 0.258).
Three patients experienced grade 4 toxicities which included an
ileal obstruction (n = 1), obstruction gastric (n = 1), and duodenal
stenosis (n = 1) all requiring urgent operative intervention. Eight
patients experienced grade 3 toxicities which included nausea
(n = 3), enteritis (n = 2), enterocolitis (n = 1), ileal hemorrhage
(n = 1), and biliary tract infection (n = 1).

provides superior 2-year LC over single fractionation, but may
not be associated with improved OS. Additionally, treatment
with either single- or multifraction SBRT was delivered with
reasonable levels of toxicity with prior radiation therapy most
predictive of late radiation toxicities. Consistent with numerous other reports, these data also support surgery as the most
important factor for OS (24).
Pollom et al. previously reported on 167 patients with unresectable pancreatic adenocarcinoma comparing single- versus
five-fraction SBRT. Median OS for all patients was 13.6 months
with 12-month survival from SBRT at 30.8 and 34.9% for single- and multifraction, respectively. The 12-month cumulative
incidence rates of local recurrence were 9.5 and 11.7% for single
and multifraction, respectively. Neither OS from SBRT nor local
recurrence demonstrated significant difference between singleand multifraction groups. Cumulative GI grade 2+ toxicity by
12 months was 26.1% for single fraction and 7.8% for multifraction
which was a significant difference (20). In contrast, our data show
a significant improvement in LC with multifraction as compared to
single-fraction regimens. This difference is most likely due to the

DISCUSSION
This retrospective review aimed to assess the role SBRT fractionation on OS and LC of pancreatic adenocarcinoma while
also determining the rates of late radiation toxicity for this
treatment modality. This study identified three-fraction SBRT
Table 2 | Univariate and multivariate analyses for overall survival (OS).
Variable
Age
CA19-9
At diagnosis
Pre-SBRT
By median (≤83 vs. <83)
≤90 vs. >90
Post-SBRT
By median (≤73 vs. >73)
≤90 vs. >90
SMAD4 mutation
Location
Prior EBRT
Treatment platform
All (Trilogy, Truebeam, CK)
Non-robotic (T/T) vs. CyberKnife
All (Trilogy, Truebeam, CK)

2-year OS

p Value

–

<0.001

–
–
–
–
–
54.1 vs. 26.4%
52.1 vs. 25.5%
–
–
39.5 vs. 27.8 vs. 35.9%
37.9 vs. 27.8%

0.001
<0.001

Dosimetry
GTV volume
GTV max dose
GTV min dose
PTV volume
By median (≤18 vs. >18 cm3)
PTV max dose
PTV min dose
PTV mean dose
Small bowel max dose
Small bowel mean dose
Single vs. multifraction
BED10 Gy

–
–
–
–
44 vs. 31.9%
–
–
–
–
–
30.5 vs. 37.5%
–

0.399
0.163
0.793
<0.001
0.033
0.847
0.529
0.982
0.365
0.179
0.019
0.151

1.01 (1.01–1.01)

0.009

Surgery
Not completed
Completed

1.00 (reference)
0.31 (0.19–0.50)

–
<0.001

Boldface values are significant predictors (p value < 0.05).
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p Value

Age

–

0.549

CA 19-9
At diagnosis
Pre-SBRT
Post-SBRT
SMAD4 mutation
Location
Prior EBRT

–
–
–
–
–
–

0.581
0.820
0.082
0.791
0.427
0.586

73.7 vs. 61.7 vs. 58.5%
68.2 vs. 58.5%

0.022
0.010

Recurrent lesion
Recurrent vs. not
Surgery (yes vs. no)

35.4 vs. 70.4%
74.1 vs. 53.9%

<0.001
0.010

Dosimetry
GTV volume
GTV max dose
GTV min dose
PTV volume
PTV max dose
PTV min dose
PTV mean dose
Small bowel max dose
Small bowel mean dose
Single vs. multifraction
BED10 Gy (continuous)

–
–
–
–
–
–
–
–
–
56.8 vs. 69.7%
–

0.419
0.145
0.223
0.260
0.196
0.753
0.213
0.657
0.355
0.004
0.052

Variable

p Value

Post-SBRT CA 19-9 (continuous)

2-year LC

Treatment platform
All (Trilogy, Truebeam, CK)
Non-robotic (T/T) vs. CyberKnife
All (Trilogy, Truebeam, CK)

0.036
0.013

69.4 vs. 30.4%
59.8 vs. 14.3%

HR (95% CI)

Variable

0.604
<0.001
0.457
0.347
0.011
<0.001
<0.001
0.968
0.283
0.241

Recurrent lesion
Recurrent vs. not
Surgery (yes vs. no)

Variable

Table 3 | Univariate and multivariate analysis for local control (LC).

HR (95% CI)

p Value

Recurrent lesion
No
Yes

1.00 (reference)
2.31 (1.32–4.05)

0.003

Fractionation scheme
Single fraction
Multifraction

1.00 (reference)
0.53 (0.33–0.85)

0.009

Boldface values are significant predictors (p value < 0.05).
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Figure 2 | Local control for single- and multifraction stereotactic body radiation therapy.

patients with recurrent disease demonstrated worse LC which
may have affected the results observed in single-fraction patients.
Although surgical resection has been shown to be the most significant predictive factor for clinical outcomes, it is unlikely playing a
role in the observed difference between different fraction regimens
as resection rates were similar between both groups. SBRT has also
been an enticing modality in the treatment of locally advanced
and borderline resectable pancreatic adenocarcinoma due to its
improved rates of LC and increased rates of resection in these
tumors (25). Although previous trials analyzing single fraction
SBRT demonstrated excellent LC, they were associated with
unacceptable rates of toxicity (18, 19). This leads to the adoption
of multifraction regimens. Chuong et al. reported on 73 patients
with borderline resectable (78.1%) and locally advanced (21.9%)
pancreatic adenocarcinoma treated with induction chemotherapy
followed by five-fraction SBRT. Borderline resectable and locally
advanced tumors experienced a median OS of 16.4 and 15 months
and a 1-year progression free survival of 42.8 and 41%, respectively, with 5.3% advanced grade 3+ toxicity (10). Mahadevan
et al. reported on 36 patients with nonmetastatic locally advanced
pancreatic cancer treated with three-fraction SBRT with a total
dose of 24, 30, or 36 Gy followed by gemcitabine therapy. Median
OS was 14.3 months; LC was 78% with a median progression-free
survival of 9.6 months and 5.5% (n = 2) developed advanced grade
3+ toxicity. Although previous reports identified unacceptable
rates of advanced toxicity with single-fraction SBRT our results
demonstrated no significant difference between single- and
multifractionation on advanced toxicity, which may reflect variances in volumes, constraints and total dose between institutions.
Additionally, as previously stated, due to early reports of high
rates of late GI toxicity, our institution limited dose to the small

significantly larger cohort used in the present study. Additional differences that may have contributed included our study reporting on
all pancreatic adenocarcinoma except those with distant metastases
as opposed to only unresectable tumors including those with distant metastases at treatment. Additionally, our multifraction group
consisted of 36 Gy in three fractions as opposed to 33 Gy in five
fractions. Finally, because the linear quadratic model in not applicable for hypofractionated treatments, there could be a difference
in BED between these two regimens which is currently unknown.
We believe our difference observed in LC between single and
multifraction SBRT is most likely a result of differences in tumor
dose. In our initial experience with single fraction SBRT there
was significant concern for bowel toxicity. In an effort to reduce
toxicity, dose to the small bowel was limited therefore compromising PTV coverage. Multifraction regimens allowed us to be less
conservative with bowel dosing and therefore allow for greater
coverage of the tumor. This would further explain why we did not
observe a difference in advanced grade 3+ toxicity between these
regimens as demonstrated by Pollom et al. These two studies seem
to demonstrate the trade-off between toxicity and LC for single
fraction SBRT. Our observed difference in LC however could also
be a result of patient demographics independent of fractionation.
As reports of increased toxicity with single fraction surfaced, our
institution slowly switched to multifraction regimens. This lead
a greater proportion of patients treated in later years received
three-fraction SBRT. It is possible this observed difference was
a result of differences in chemotherapy; however, chemotherapy
regimens were poorly reported and demonstrated significant heterogeneity between and within single- and multifraction cohorts.
Additionally, there was higher proportion of recurrent disease
in those treated with single fraction SBRT. As we have shown,
Frontiers in Oncology | www.frontiersin.org
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Table 4 | Univariate and multivariate analysis for regional control (RC).
Variable
Age

Table 5 | Univariate and multivariate analysis for distant metastasis (DM).

2-year RC

p Value

–

0.271

CA 19-9
At diagnosis
Pre-SBRT
Post-SBRT
By median (≤73 vs. >73)
≤90 vs. >90
SMAD4 mutation
Location
Prior EBRT

–
–
–
–
–
–
–
–

0.535
0.413
0.020
0.580
0.891
0.677
0.942
0.677

Treatment platform
All (Trilogy, Truebeam, CK)
Non-robotic (T/T) vs. CyberKnife

–
–

0.735
0.725

Recurrent lesion
Recurrent vs. not
Surgery (yes vs. no)

–
–

0.137
0.434

Dosimetry
GTV volume
GTV max dose
GTV min dose
PTV volume
PTV max dose
PTV min dose
PTV mean dose
Small bowel max dose
Small bowel mean dose
Single vs. multifraction
BED10 Gy (continuous)

–
–
–
–
–
–
–
–
–
–
–

0.685
0.904
0.761
0.752
0.958
0.608
0.789
0.748
0.600
0.541
0.067

HR (95% CI)

p Value

1.01 (1.01–1.01)

0.020

Variable
Post-SBRT CA 19-9

Variable
Age
CA 19-9
At diagnosis
Pre-SBRT
By median (≤83 vs. >83)
≤ 90 vs. >90
Post-SBRT
By median (≤73 vs. >73)
≤90 vs. >90
SMAD4 mutation
Location
Prior EBRT
Treatment platform
All (Trilogy, Truebeam, CK)
Non-robotic (T/T) vs. CyberKnife
Recurrent lesion
Recurrent vs. not
Surgery (yes vs. no)
Dosimetry
GTV volume
GTV max dose
GTV min dose
PTV volume
PTV max dose
PTV min dose
PTV mean dose
Small bowel max dose
Small bowel mean dose
Single vs. multifraction
BED10 Gy (continuous)
Variable
Post-SBRT CA 19-9

Boldface values are significant predictors (p value < 0.05).

2-year DM

p Value

–

0.348

–
–
48.9 vs. 59.8%
50.3 vs. 59.2%
–
41.8 vs. 70.8%
47.7 vs. 66.6%
–
–
–

0.041
0.001
0.039
0.054
0.006
0.004
0.067
0.696
0.745
0.815

–
–

0.467
0.163

–
–

0.586
0.124

–
–
–
–
–
–
–
–
–
–
–

0.664
0.380
0.694
0.564
0.480
0.176
0.900
0.487
0.499
0.226
0.429

HR (95% CI)

p Value

1.01 (1.01–1.01)

0.001

Boldface values are significant predictors (p value < 0.05).

bowel in an attempt to minimize toxicity rates. Our lack of ability
to identify differences in toxicity could also be secondary to the
inherent limitation of retrospective studies.
Stereotactic body radiation therapy has also been identified as
an effective treatment modality in treatment of recurrent lesions
following resection. Dagolglu et al. reported on 30 patients treated
with SBRT for recurrent pancreatic cancer with prior radiation
therapy. Patients received a median of 25 Gy in five fractions.
Median OS was 14 months, 2-year LC was 78, and 7% advanced
grade 3+ toxicity (26). Here, we reported significantly greater risk
of advanced toxicity with prior radiation therapy while Dagolglu
et al. demonstrated reasonable toxicity in patients with prior
radiation. The lower toxicity seen with Dagolglu et al. could be
secondary to the five fraction regimen used as opposed to the
three fractions or one fraction mostly used in our study. Also,
25 Gy in five fractions has a lower biological effective dose than
our regimens, which may compromise LC.
Herman et al. recently reported on a multi-institutional study
combining Gemcitabine with five-fraction SBRT in patients with
locally advanced pancreatic cancer (27). Forty-nine patients with
locally advanced patients were treated with up to three doses of
Gemcitabine (1,000 mg/m2) followed by a 1-week break and then
SBRT, 33 Gy in five fractions over 1–2 weeks. After SBRT, patients
were continued on Gemcitabine until progression. Median OS
was 14 months and 2-year OS was 18%. Freedom from local
Frontiers in Oncology | www.frontiersin.org

progression at 1-year was 78%. On multivariate analysis PET
positive disease prior to SBRT and CA19-9 > 90 after SBRT were
associated with an increased risk of death. Acute grade 2 plus
toxicity included enteritis, gastritis and ulcer. There was 1 grade
4 toxicity of a duodenal fistula. There was 11% advanced grade
2 or greater toxicity, again mostly enteritis, gastritis, and ulcer.
Their advanced toxicity was low like ours showing feasibility of
multifraction regimens.
We showed higher post-SBRT CA 19-9 were associated with
lower survival and higher rates of regional and DM. This is similar
to the results reported by Herman et al, who showed post-SBRT values greater than 90 were associated with a lower survival on multivariate analysis (27). These results of post-SBRT CA19-9 associated
with survival but not CA19-9 at diagnosis or pre-SBRT indicate
posttreatment CA19-9 as a surrogate for treatment efficacy. Similar
data have been reported in the literature identifying a decrease in
CA19-9 following treatment to be a predictor of OS (28–30). Future
trials evaluating the role of SBRT for pancreatic carcinoma should
consider evaluating the affect SBRT has on CA19-9 values.
This study adds to the current growing body of literature that
demonstrates the effectiveness and tolerability of SBRT for pancreatic adenocarcinoma. Following the initial reports demonstrating
unacceptably high rates of advanced GI toxicity with single fraction
SBRT, many institutions transitioned to multifraction regimens.
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disease, as well as patients with prior EBRT. Additionally, as this
was a retrospective review the breakdown of patients within oneand three-fraction SBRT were not matched. Another limitation
was our inability to capture detailed chemotherapy data on these
patients. As patients with single fraction were treated in earlier
years it is possible there is an unseen effect of advancements in
chemotherapy over time. Regarding toxicity, although we report
very low rates, this may be artificially low due to uncaptured
toxicity associated with retrospective reports. However, our low
toxicity rates are possibly secondary to our institution editing the
PTV out of the bowel to reduce toxicity. Finally, CA19-9 levels
and SMAD4 mutation status were not obtained in all patients,
likely due to limited testing. Prospective studies will be needed to
provide a more rigorous analysis of the role of SBRT fractionation
in pancreatic adenocarcinoma as well as the possible contribution
of SMAD4 mutation status and evolving systemic therapy on LC.

Table 6 | Kaplan–Meier estimates for various end points.
End point

Kaplan–Meier
estimate (95%
confidence interval)

Median follow-up
From SBRT (months) (IQ range)

17.3 (10.1–29.3)

Median survival
Median survival (months) (95% CI)
12 months (95% CI)
24 months (95% CI)

17.8 (15.7–20.0)
69.7 (64.4–75.0)
35.3 (29.8–40.9)

Local control from SBRT
12 months (95% CI)
24 months (95% CI)

73.7 (67.6–79.8)
66.1 (58.5–73.4)

Regional control from SBRT
12 months (95% CI)
24 months (95% CI)

89.2 (84.9–93.5)
86.3 (81.0–91.6)

Distant metastases from SBRT
12 months (95% CI)
24 months (95% CI)

39.5 (33.0–46.0)
56.4 (48.6–64.2)

Toxicity
Grade 2+ toxicity
1-year toxicity (95% CI)
2-year toxicity (95% CI)
Grade 3+ toxicity
1-year toxicity (95% CI)
2-year toxicity (95% CI)

CONCLUSION
This single institution retrospective review of 291 patients with
pancreatic adenocarcinoma identified multifraction regimens
SBRT had a higher LC than single fractionation regimens.
Although multifraction regimens displayed a higher OS on univariate analysis it did not hold significance on MVA. Post-SBRT
CA19-9 was found to be significant factor for OS, RC, and DM.
Finally, we showed low rates of advanced grade 2+ and grade 3+
toxicity associated with SBRT. This single institution report is the
largest retrospective series showing multifraction regimens SBRT
is associated with a higher LC than single fractionation regimens.

7.8 (4.7–10.9)
7.8 (4.7–10.9)
2.5 (2.3–2.7)
2.5 (2.3–2.7)

Univariable analysis for advanced toxicities
Variable (grade 2+advanced toxicity)
Prior radiotherapy
GTV volume
PTV volume
Treatment platform
Single vs. multifraction
Small bowel max dose
Small bowel mean dose
Variable (grade 3+ advanced toxicity)
Prior radiotherapy
GTV volume
PTV volume
Treatment platform
Single vs. multifraction
Small bowel max dose
Small bowel mean dose

HR (95% CI)

p Value

3.26 (1.33–8.00)
–
–
–
–
–
–

0.010
0.201
0.736
0.57
0.737
0.955
0.774

HR (95% CI)

p Value

4.58 (1.29–16.21)
–
–
–
–
–
–
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Despite previous reports indicating multifraction SBRT produced
decreased rates of toxicity, it was unclear whether this came at
the cost of other clinical outcomes. Through analyzing the largest cohort comparing single to multifraction SBRT, we identified
multifraction treatment schedules to be associated with improved
LC while reinforcing the significant role surgery and CA19-9
levels play in prognosis (2, 18, 31–34). These results support the
continued use of multifraction regimens. Taken together with prior
work, multifraction SBRT appears to provide either improved LC
or reduced rates of toxicity as compared to single fraction (20).
Despite the above study showing a significant difference in LC
between SBRT fractionation, there were numerous limitations to
this work. Our cohort represented a very heterogeneous population as it included resected and unresected disease, recurrent
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